Sector Pharmaceuticals & Biotech. - Latest news, views and updates

SECTOR | 15 Jan 2026

Biocon raises 4,150 crore via QIP issue on strong investor demand

Business Standard

Biotech firm Biocon on Thursday said it has raised Rs 4,150 crore through a Qualified Institutions Placement (QIP) process. The initiative saw issuance of 1,12,664,585 equity shares of face value Rs 5 each to eligible qualified institutional buyers at the issue price of Rs 368.35 per share, the Bengaluru-based firm said in a regulatory filing. The QIP, which opened on January 12 and closed on January 14, attracted strong investor interest from a broad mix of domestic and international participants, reflecting robust confidence in the company's growth prospects, it added. The proceeds from the QIP will be primarily utilised to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics Ltd, including repayment of debt availed in this regard, Biocon said. The company recently announced its board has approved a strategic corporate action to acquire all remaining minority shareholdings, including Viatris' stake, thereby making Biocon

Axis Direct released a Sector Update report for Pharmaceuticals & Biotech. on 07 Jan, 2026.

Biocon raises 4,150 cr via QIP issue

Business Line | 15 Jan 2026

Pharmaceuticals & Biotech.

SECTOR | 12 Jan 2026

Biocon Opens Rs 4,500-Crore QIP To Fund Biologics Integration

NDTV Profit

Of the total proceeds via the share sale, up to Rs 3,620 crore will be utilised mainly towards payment to Mylan Inc. (Viatris).

Axis Direct released a Sector Update report for Pharmaceuticals & Biotech. on 07 Jan, 2026.

Pharmaceuticals & Biotech.

SECTOR | 07 Jan 2026

Lupin, Zydus Lifesciences Among DRChoksey's Top Picks As Pharma Sector Braces For Q3 Check Full List

NDTV Profit

Other notable picks include Alembic Pharma which is expected to benefit from specialty optionality and margin improvement.

Axis Direct released a Sector Update report for Pharmaceuticals & Biotech. on 07 Jan, 2026.

Pharmaceuticals & Biotech.

SECTOR | 07 Jan 2026

Q3FY26 Earnings Preview - Pharma and Healthcare

Pharmaceuticals & Biotech.

Axis Direct

Our Top Earnings Plays: Lupin, Biocon and Fortis.

Axis Direct released a Sector Update report for Pharmaceuticals & Biotech. on 07 Jan, 2026.

Pharmaceuticals & Biotech.

SECTOR | 05 Jan 2026

Q3FY26E Pharmaceuticals Sector Preview

Pharmaceuticals & Biotech.

Deven Choksey

For our pharma coverage universe, we expect Revenue to be largely steady at INR 644,525 mn in Q3FY26E, translating into 3.7% YoY growth and a marginal -0.3% QoQ.

Axis Direct released a Sector Update report for Pharmaceuticals & Biotech. on 07 Jan, 2026.

Pharmaceuticals & Biotech.

SECTOR | 01 Jan 2026

Will Zaynich Drug's Fast-Track Review Speed Europe Approval?

NDTV Profit

Wockhardt Group's Zaynich drug, a novel antibiotic combination of Zidebactum and Cefepime, has received fast-track review status from the European Medicines Agency (EMA) for the treatment of serious bacterial infections, including severe urinary infections, hospital-acquired pneumonia, and life-threatening blood infections.

Axis Direct released a Sector Update report for Pharmaceuticals & Biotech. on 07 Jan, 2026.

Pharmaceuticals & Biotech.

SECTOR | 31 Dec 2025

US commits $480 mn to Ivory Coast health sector under 'America First' pact

Business Standard

The United States and Ivory Coast signed a health deal Tuesday requiring the U.S. to commit USD 480 million to the West African nation's health sector as part of America First global health funding pacts that mirror the Trump administration's foreign policy. The signing in Ivory Coast's capital of Abidjan covers areas such as HIV, malaria, maternal and child health, and global health security. It is the latest agreement the U.S. has entered with more than a dozen African countries, most of them hit by U.S. aid cuts, including Ivory Coast. U.S. aid cuts have crippled health systems across the developing world, including in Africa, where many countries relied on the funding for crucial programs, including those responding to outbreaks of disease. The new health pact is based on the principle of shared responsibility with Ivory Coast committing to provide up to 163 billion CFA francs (USD 292 million) by 2030, representing 60% of the overall commitment, according to Ivorian Prime...

Axis Direct released a Sector Update report for Pharmaceuticals & Biotech. on 07 Jan, 2026.

Pharmaceuticals & Biotech.

SECTOR | 17 Dec 2025

Madhya Pradesh forms panel to probe HIV infection among 6 children

Business Standard

The Madhya Pradesh government has formed a six-member committee to investigate how six children suffering from blood disorder thalassemia, including four treated at a hospital in Satna, contracted HIV infection, officials said. Tarun Rathi, Commissioner of the Public Health and Medical Education Department, issued an order on Tuesday announcing the formation of the investigation team and directed it to submit a report within seven days. The six children in the age group of 12 to 15 were found to be HIV positive after suspected contaminated blood transfusions at the district hospitals in Satna, Jabalpur and elsewhere. The parents of one of them were also found to be infected, officials said on Tuesday. Satna Collector Satish Kumar S told reporters that these infection cases came to light between January and May this year, and all the victims are currently undergoing treatment. "Children suffering from thalassemia were receiving regular blood transfusions. Six of them were found to b

Axis Direct released a Sector Update report for Pharmaceuticals & Biotech. on 07 Jan, 2026.

Pharmaceuticals & Biotech.

SECTOR | 16 Dec 2025

Odisha unveils Pharma, MedTech Policy 2025, eyes 25,000 crore investment

Business Standard

The Odisha government on Tuesday unveiled Pharmaceutical and Medical Devices Policy-2025, aiming to attract investment of Rs 25,000 crore and create 1 lakh jobs by 2030. Chief Minister Mohan Charan Majhi launched the new policy here at the Odisha Pharma Summit-2025 in the presence of Industries Minister Sampad Chandra Swain and senior government officers. Speaking on the occasion, Industries Department's Additional Chief Secretary Hemant Sharma said India imports about 85 per cent of medical devices from other countries, and there is a huge opportunity for this sector. As a lot of units of pharmaceutical and medical devices are expected to come up in the next five years, Odisha must make an attempt to become a part of this endeavour, Sharma said. Under the policy, the state offers a 50 per cent subsidy on concessional land cost for units employing more than 200 Odisha-domiciled skilled staff. The government also offered a 30 per cent capital subsidy on eligible plant and machinery

Axis Direct released a Sector Update report for Pharmaceuticals & Biotech. on 07 Jan, 2026.

Pharmaceuticals & Biotech.

SECTOR | 15 Dec 2025

Biocon launches drugs for diabetes and obesity treatment in Netherlands

Business Standard

The Netherlands launch builds on Biocon's entry into the UK in February, where it received regulatory approval for liraglutide from the Medicines and Healthcare Products Regulatory Agency

Axis Direct released a Sector Update report for Pharmaceuticals & Biotech. on 07 Jan, 2026.